Patrick MBA - Protara Therapeutics Chief Officer
| TARA Stock | USD 4.55 0.08 1.73% |
Executive
Patrick MBA is Chief Officer of Protara Therapeutics
| Age | 57 |
| Address | 345 Park Avenue South, New York, NY, United States, 10010 |
| Phone | 646 844 0337 |
| Web | https://www.protaratx.com |
Protara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2811) % which means that it has lost $0.2811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4591) %, meaning that it created substantial loss on money invested by shareholders. Protara Therapeutics' management efficiency ratios could be used to measure how well Protara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 19, 2025, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 16.9 M, whereas Net Tangible Assets are forecasted to decline to about 71.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Katarina MD | Xilio Development | 49 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Mo Qatanani | Scholar Rock Holding | 52 | |
| Catherine Hu | Scholar Rock Holding | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Erin Moore | Scholar Rock Holding | 49 | |
| David MS | Ikena Oncology | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 53 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Erin CPA | Scholar Rock Holding | 50 | |
| Caroline Hensley | Xilio Development | N/A | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Lisa Price | Scholar Rock Holding | N/A | |
| Ryan Iarrobino | Scholar Rock Holding | N/A | |
| Junlin JD | Scholar Rock Holding | 46 | |
| Bob Lally | Ikena Oncology | N/A | |
| Julissa Viana | Xilio Development | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 |
Protara Therapeutics Leadership Team
Elected by the shareholders, the Protara Therapeutics' board of directors comprises two types of representatives: Protara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protara. The board's role is to monitor Protara Therapeutics' management team and ensure that shareholders' interests are well served. Protara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA MPH, VP CoFounder | ||
| Jesse Shefferman, Principal CoFounder | ||
| Jathin MD, Executive Officer | ||
| Justine OMalley, Senior Affairs | ||
| Kristine Rosse, VP Officer | ||
| Patrick MBA, Chief Officer | ||
| Hannah Fry, Principal Controller | ||
| Mary Grendell, General Secretary |
Protara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 84.17 M | ||||
| Shares Outstanding | 34.76 M | ||||
| Shares Owned By Insiders | 6.12 % | ||||
| Shares Owned By Institutions | 51.10 % | ||||
| Number Of Shares Shorted | 5.1 M | ||||
| Price To Book | 1.97 X | ||||
| EBITDA | (43.27 M) | ||||
| Net Income | (40.42 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.